Filter Results:
(1,248)
Show Results For
- All HBS Web
(1,248)
- People (5)
- News (172)
- Research (929)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
Show Results For
- All HBS Web
(1,248)
- People (5)
- News (172)
- Research (929)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
- October 2007
- Case
Valuation at Novartis
By: Paul M. Healy
Healy, Paul M. "Valuation at Novartis." Harvard Business School Case 108-041, October 2007.
- October 2006
- Teaching Note
Merck Sharp & Dohme Argentina, Inc. (TN) (A) and (B) (LCA)
By: Lynn S. Paine
- April 2006
- Supplement
Vertex Pharmaceuticals: R&D Portfolio Management (C)
By: Francesca Gino and Gary P. Pisano
Keywords: Pharmaceutical Industry
Gino, Francesca, and Gary P. Pisano. "Vertex Pharmaceuticals: R&D Portfolio Management (C)." Harvard Business School Supplement 606-117, April 2006.
- April 2006
- Supplement
Vertex Pharmaceuticals: R&D Portfolio Management (B)
By: Francesca Gino and Gary P. Pisano
Keywords: Pharmaceutical Industry
Gino, Francesca, and Gary P. Pisano. "Vertex Pharmaceuticals: R&D Portfolio Management (B)." Harvard Business School Supplement 606-116, April 2006.
- April 1989 (Revised July 1992)
- Supplement
Technology Transfer: Anti-Inflammatory Drug (B)
Herzlinger, Regina E. "Technology Transfer: Anti-Inflammatory Drug (B)." Harvard Business School Supplement 189-166, April 1989. (Revised July 1992.)
- February 2006 (Revised July 2007)
- Case
Corporate Venture Capital at Eli Lilly
By: Richard G. Hamermesh, Ron Laufer and David Lane
Reviews the role of corporate venture capital and its history at Eli Lilly. Also presents a challenging venture investment opportunity. View Details
Hamermesh, Richard G., Ron Laufer, and David Lane. "Corporate Venture Capital at Eli Lilly." Harvard Business School Case 806-092, February 2006. (Revised July 2007.)
- January 2006 (Revised July 2006)
- Case
Drug Testing in Nigeria (A)
By: Debora L. Spar
In 1996, a meningitis epidemic swept across Nigeria. Thousands of children were struck and, lacking appropriate medicine, were liable to die from the disease. Doctors at Pfizer had an antibiotic that could probably save most of these children's lives. The drug was new,... View Details
Keywords: Risk and Uncertainty; Health Pandemics; Health Testing and Trials; Developing Countries and Economies; Pharmaceutical Industry; Nigeria
Spar, Debora L., and Adam Day. "Drug Testing in Nigeria (A)." Harvard Business School Case 706-033, January 2006. (Revised July 2006.)
- fall 2002
- Article
Science and Medicine in Court: Expert Testimony in the German Thalidomide Trial
By: Arthur A. Daemmrich
Daemmrich, Arthur A. "Science and Medicine in Court: Expert Testimony in the German Thalidomide Trial." Chemical Heritage, no. 20 (fall 2002): 12–13, 28–33.
- March 2001 (Revised June 2017)
- Teaching Note
Vyaderm Pharmaceuticals: The EVA Decision
By: Robert Simons and Indra A. Reinbergs
Teaching Note for (9-101-019). View Details
- October 2000
- Supplement
Hans Fritz at Novartis Thailand (C)
By: Carin-Isabel Knoop and Michael Y. Yoshino
Supplements the (A) case. View Details
Knoop, Carin-Isabel, and Michael Y. Yoshino. "Hans Fritz at Novartis Thailand (C)." Harvard Business School Supplement 301-054, October 2000.
- October 2000
- Case
Procter & Gamble Italy: The Pringles Launch (A)
By: Roy D. Shapiro
Procter & Gamble's (P&G) Pringles potato chips have been a very successful brand. This case reviews the development and first launch in the United States, then in markets around the world. Italy is one of the last countries where Pringles will be launched. Should P&G... View Details
Keywords: Globalized Markets and Industries; Brands and Branding; Marketing Strategy; Product Launch; Emerging Markets; Product Development; Adoption; Value Creation; Pharmaceutical Industry; United States
Shapiro, Roy D. "Procter & Gamble Italy: The Pringles Launch (A)." Harvard Business School Case 601-070, October 2000.
- September 1999
- Teaching Note
Eli Lilly: The Evista Project TN
Teaching Note for (9-699-016). View Details
Keywords: Pharmaceutical Industry
- June 1998
- Supplement
MBA Integrative Exercise: General Management, April 1998
By: Carin-Isabel Knoop
Drummond Paris, Regional Pharma Head, Asia/Pacific Novartis AG, discusses the company situation in Indonesia: joint ventures, budget, keeping track, and the prognosis for the future. View Details
Keywords: Business or Company Management; Joint Ventures; Forecasting and Prediction; Pharmaceutical Industry; Indonesia
Knoop, Carin-Isabel. "MBA Integrative Exercise: General Management, April 1998." Harvard Business School Video Supplement 898-503, June 1998.
- October 1992 (Revised September 1993)
- Case
Nopane Advertising Strategy
By: David E. Bell
Nopane is a proprietary drug that sells in much of the United States. It faces substantial competition. The brand manager is undertaking an experiment to determine whether ad copy should be emotional-based or rational-based. The data and associated regression results... View Details
Keywords: Competition; Intellectual Property; Advertising; Health Care and Treatment; Brands and Branding; Product Marketing; Pharmaceutical Industry; United States
Bell, David E. "Nopane Advertising Strategy." Harvard Business School Case 893-005, October 1992. (Revised September 1993.)
- February 1998 (Revised October 1998)
- Background Note
Note on New Drug Development in the United States
By: Stefan H. Thomke and Ashok Nimgade
An overview of the new drug development process in the United States, using the migraine drug Imitrex as an illustrative example. View Details
Keywords: Product Development; Research and Development; Health; Pharmaceutical Industry; United States
Thomke, Stefan H., and Ashok Nimgade. "Note on New Drug Development in the United States." Harvard Business School Background Note 698-028, February 1998. (Revised October 1998.)
- February 1996 (Revised April 2004)
- Case
Eli Lilly and Company: Innovation in Diabetes Care
By: Clayton M. Christensen
Summarizes Eli Lilly's history of innovation in its business, describing how the dimensions along which innovations have been made in the industry have changed. Lilly's innovation strategy has been to pursue ever higher performance products, while others in the... View Details
Keywords: Change; Product; Service Delivery; Product Development; Innovation and Management; Innovation Strategy; Health Care and Treatment; Pharmaceutical Industry
Christensen, Clayton M. "Eli Lilly and Company: Innovation in Diabetes Care." Harvard Business School Case 696-077, February 1996. (Revised April 2004.)
- August 1995
- Teaching Note
Eli Lilly and Company: The Flexible Facility Decision (1993) TN
By: Gary P. Pisano
Teaching Note for (9-694-074). View Details
Keywords: Pharmaceutical Industry
- February 1987 (Revised January 1989)
- Case
SmithKline Consumer Products: The Contac Relaunch
In March 1986, a tamperer contaminated CONTAC Cold Capsules, SmithKline Consumer Product's most popular product. To relaunch CONTAC after withdrawing it from the market, the management team had to present a plan of action to the corporation board. They knew CONTAC's 25... View Details
Kosnik, Thomas J. "SmithKline Consumer Products: The Contac Relaunch." Harvard Business School Case 588-046, February 1987. (Revised January 1989.)
- February 1974
- Case
Listerine Lozenges
Greyser, Stephen A. "Listerine Lozenges." Harvard Business School Case 574-062, February 1974.
- February 1992 (Revised April 1995)
- Case
Pfizer: Global Protection of Intellectual Property
By: Lynn S. Paine and Michael Santoro
Top officials at Pfizer are assessing their strategy for improving protection of Pfizer's patents around the world. The outcome of the Uruguay Round of the GATT negotiations is uncertain, and it is not clear whether an acceptable intellectual property protection... View Details
Keywords: Patents; Trade; Policy; Government and Politics; Business Strategy; Agreements and Arrangements; Alliances; Cross-Cultural and Cross-Border Issues; Pharmaceutical Industry; United States; Japan; Europe
Paine, Lynn S., and Michael Santoro. "Pfizer: Global Protection of Intellectual Property." Harvard Business School Case 392-073, February 1992. (Revised April 1995.)